1. Subjects who are able to provide a written informed consent or have a legally accepted representative to provide the same. <br/ >2. Subjects who are proven to be positive for SARS-CoV-2 infection, as confirmed by the RT-PCR test. <br/ >3. Subjects who are admitted with moderate COVID-19 (MOFHW criteria) for treatment at the hospital having the following clinical criteria: pneumonia with no signs of severe disease, peripheral capillary oxygen saturation (SPO2) between 90 and 94% on room air and respiratory rate between 15 and 30 breaths per minute. <br/ >4. Subjects with arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) between 200 and 300 mm/Hg. <br/ >5. Female subjects with a negative urine pregnancy test at screening. <br/ >6. Subjects who are able to take the study drug orally and comply with the study procedures

1. Subjects who are able to provide a written informed consent or have a legally accepted representative to provide the same. <br/ >2. Subjects who are proven to be positive for SARS-CoV-2 infection, as confirmed by the RT-PCR test. <br/ >3. Subjects who are admitted with moderate COVID-19 (MOFHW criteria) for treatment at the hospital having the following clinical criteria: pneumonia with no signs of severe disease, peripheral capillary oxygen saturation (SPO2) between 90 and 94% on room air and respiratory rate between 15 and 30 breaths per minute. <br/ >4. Subjects with arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) between 200 and 300 mm/Hg. <br/ >5. Female subjects with a negative urine pregnancy test at screening. <br/ >6. Subjects who are able to take the study drug orally and comply with the study procedures

1. Subjects who are able to provide a written informed consent or have a legally accepted representative to provide the same. <br/ >2. Subjects who are proven to be positive for SARS-CoV-2 infection, as confirmed by the RT-PCR test. <br/ >3. Subjects who are admitted with moderate COVID-19 (MOFHW criteria) for treatment at the hospital having the following clinical criteria: pneumonia with no signs of severe disease, peripheral capillary oxygen saturation (SPO2) between 90 and 94% on room air and respiratory rate between 15 and 30 breaths per minute. <br/ >4. Subjects with arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) between 200 and 300 mm/Hg. <br/ >5. Female subjects with a negative urine pregnancy test at screening. <br/ >6. Subjects who are able to take the study drug orally and comply with the study procedures

1. Subjects who are able to provide a written informed consent or have a legally accepted representative to provide the same. <br/ >2. Subjects who are proven to be positive for SARS-CoV-2 infection, as confirmed by the RT-PCR test. <br/ >3. Subjects who are admitted with moderate COVID-19 (MOFHW criteria) for treatment at the hospital having the following clinical criteria: pneumonia with no signs of severe disease, peripheral capillary oxygen saturation (SPO2) between 90 and 94% on room air and respiratory rate between 15 and 30 breaths per minute. <br/ >4. Subjects with arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) between 200 and 300 mm/Hg. <br/ >5. Female subjects with a negative urine pregnancy test at screening. <br/ >6. Subjects who are able to take the study drug orally and comply with the study procedures